군발 두통 : 시장 인사이트, 역학 및 예측(2036년)

Cluster Headache Insights and Trends

• According to the National Organization of Rare Diseases (NORD), cluster headache is an uncommon, severe form of primary neurovascular headache. Cluster headache are the most painful form of headache, with the pain occurring on one side of the head and behind or above the eye or at the temple most commonly.
• Cluster headache is the most common type of trigeminal autonomic cephalalgia and affects approximately 0.1% of the population. Despite its rarity, it is considered one of the most severe and debilitating headache disorders, making early diagnosis and effective treatment essential.
• Research suggests anywhere between 30 to 80% of patients with cluster headaches also have sleep apnea.
• Cluster headache is classified into episodic and chronic forms. Episodic cluster headache is characterized by recurrent cluster periods lasting 7 days to 1 year, separated by remission periods of at least 1 month, whereas chronic cluster headache persists for more than 1 year with no remission or remission lasting less than 1 month.
• A family history of cluster headache is a significant risk factor, with individuals being 14-39 times more likely to develop the condition if a first-degree relative is affected and 2-8 times more likely if a second-degree relative has the diagnosis. An increased incidence has also been observed among individuals with a history of head trauma.
• Cluster headache treatment consists of acute, preventive, and transitional therapies, with prevention being the primary goal. Triptans are the mainstay of acute treatment, while galcanezumab (EMGALITY) is currently the only FDA-approved therapy for episodic cluster headache.
• The therapeutic pipeline for cluster headache remains highly limited, with currently no significant drug candidates in active clinical development, highlighting the substantial unmet need for novel and effective treatment options.

DelveInsight's 'Cluster Headache - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the acute pancreatitis, historical and forecasted epidemiology, as well as the Cluster Headache market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Cluster Headache market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Cluster Headache patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Cluster Headache and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Cluster Headache Market

• Improved understanding of cluster headache pathophysiology and biomarkers

Advances in understanding the roles of the hypothalamus, trigeminal-autonomic pathways, and CGRP have facilitated the development of targeted therapies. Combined with increasing disease awareness, improved diagnosis, and better access to specialized care, these advances are driving growth in the cluster headache market.

• Strong unmet need for effective preventive and acute treatments

The cluster headache treatment landscape is evolving with increasing research into CGRP-targeted therapies, neuromodulation approaches, and novel preventive and acute treatment options aimed at reducing attack frequency and severity. Emerging pipeline therapies targeting neuroinflammatory pathways, trigeminal autonomic mechanisms, and hypothalamic signaling are expected to support future therapeutic innovation beyond conventional oxygen therapy and triptan-based management.

Cluster Headache Understanding and Treatment Algorithm

Cluster Headache Overview and Diagnosis

Cluster headache is a severe neurological disorder characterized by recurrent attacks of intense unilateral head pain, typically centered on the eye or temple, and often accompanied by autonomic symptoms such as tearing, nasal congestion, eyelid swelling, facial sweating, and restlessness. Attacks usually occur in clusters over weeks or months, followed by remission periods, although some patients experience chronic forms without significant remission. The exact cause remains unclear, but hypothalamic dysfunction, trigeminal nerve activation, genetic predisposition, smoking, and alcohol consumption are considered important contributing factors. Diagnosis is primarily based on clinical presentation and headache patterns, supported by neuroimaging to exclude secondary causes. Current treatment focuses on rapid symptom relief with oxygen therapy and triptans for acute attacks, while preventive therapies such as verapamil, corticosteroids, lithium, and CGRP-targeting agents are used to reduce attack frequency and severity.

Diagnosis of Cluster headache is primarily based on clinical evaluation, characteristic headache patterns, and associated autonomic symptoms. Patients typically present with severe unilateral orbital, supraorbital, or temporal pain accompanied by symptoms such as lacrimation, nasal congestion, conjunctival injection, eyelid edema, facial sweating, or restlessness occurring in recurrent cluster periods. Diagnosis is guided by established clinical criteria and detailed patient history, while neuroimaging techniques such as MRI or CT scans are often performed to exclude secondary neurological or structural causes. Additional assessments may also be used to differentiate cluster headache from migraine, trigeminal neuralgia, and other primary headache disorders.

Cluster Headache Treatment

Treatment of Cluster headache primarily focuses on rapid relief of acute attacks, prevention of recurrent episodes, and reduction of disease burden. Acute management commonly includes high-flow oxygen therapy and triptans such as sumatriptan or zolmitriptan to quickly alleviate severe headache attacks. Preventive treatment is aimed at reducing attack frequency and severity, with commonly used therapies including verapamil, corticosteroids, lithium, and calcitonin gene-related peptide (CGRP)-targeting agents. In refractory or chronic cases, neuromodulation techniques or surgical interventions may be considered. Overall, treatment is individualized based on attack frequency, disease subtype, patient response, and tolerability to therapy.

Cluster Headache Unmet Needs

The section "unmet needs of acute pancreatitis" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Limited Long-Term Preventive Treatment Options

2. Delayed Diagnosis and Misdiagnosis

3. Lim High Disease Burden and Impact on Quality of Life, and others.....

Cluster Headache Epidemiology

Key Findings from Cluster Headache Epidemiological Analysis and Forecast

• Cluster headache affects approximately one in every 1,000 adults, with a marked male predominance where the male-to-female ratio can range from 3:1 up to 7:1 in some studies.
• Cluster headache can develop at any age, although onset most commonly occurs around 30 years of age.
• According to DelveInsight's analysis in 2025, the total prevalent cases of cluster headache accounted for nearly 890,000 in the 7MM. The highest number of cases was seen in the US. These cases are expected to increase by 2036 at a significant CAGR.
• There were approximately 144,000 males and nearly 62,000 females affected by Cluster headache in the United States in 2025, and it is estimated that the gender-specific diagnosed prevalent cases of cluster headache will increase in the forecast period.
• As per estimates based on DelveInsight's epidemiology model for Cluster Headache, Japan had about 152,500 prevalent cases of Cluster headache in 2025. These cases are anticipated to decrease by 2036.

Cluster Headache Drug Analysis & Competitive Landscape

The Cluster Headache drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the acute pancreatitis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the acute pancreatitis therapeutics market.

Approved Therapies for Cluster Headache

Galcanezumab (EMGALITY): Eli Lilly

Galcanezumab (EMGALITY) is a humanized monoclonal antibody that targets calcitonin gene-related peptide (CGRP), a key mediator involved in headache pathophysiology. Administered subcutaneously, it represents an innovative treatment approach and is the first and only FDA-approved CGRP-targeting antibody for both migraine and episodic cluster headache. In June 2019, Eli Lilly and Company announced that the US FDA had approved galcanezumab injection (300 mg) for the treatment of episodic cluster headaches in adults. Galcanezumab was first approved by the FDA in September 2018 for the preventive treatment of migraine in adults and is contraindicated in patients with serious hypersensitivity to galcanezumab or any of the excipients. In November 2018, galcanezumab was approved for use in the European Union for the prophylaxis of migraine in adults who have at least four migraine days per month.

Cluster Headache Key Players, Market Leaders, and Emerging Companies

• Eli Lilly

Drug Class Insights

Cluster Headache Market Outlook

The treatment of cluster headache can be divided into three treatment phases: a fast-acting abortive treatment, preventive drugs, and transitional treatment to bridge the period between patients starting preventive drug dosages and the drugs asserting an effect. The main goal in cluster headache treatment should always be to prevent all attacks. Unfortunately, attack freedom cannot always be achieved, especially in patients with chronic cluster headache. For these patients, it is vital to have effective attack treatment options and to achieve the best effect/side effect ratio in close collaboration with the patient.

Subcutaneous sumatriptan and high-flow oxygen remain the first-line acute treatments for cluster headache, while verapamil, lithium, and topiramate are the preferred preventive therapies. Transitional treatments are commonly used until preventive medications achieve therapeutic efficacy. Despite the significant disease burden, the treatment landscape remains largely unchanged, with galcanezumab as the only approved targeted therapy for episodic cluster headache and currently no notable emerging therapies in active clinical development, highlighting a substantial unmet need for novel treatment options.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Cluster Headache (2022-2036 Forecast)

Monoclonal Antibodies: Monoclonal antibodies, such as galcanezumab, target the CGRP pathway involved in the pathophysiology of Cluster headache, helping reduce attack frequency and improve symptom control.

Cluster Headache Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the acute pancreatitis drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Cluster Headache

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Cluster Headache Therapies Price Scenario & Trends

Pricing and analogue assessment of acute pancreatitis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report...

Industry Experts and Physician Views for Cluster Headache

To keep up with acute pancreatitis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging acute pancreatitis therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in acute pancreatitis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Johns Hopkins University, Universitats medizin Berlin, Osaka University Hospital, Erasmus University Medical Center Rotterdam etc., were contacted. Their opinion helps understand and validate current and emerging acute pancreatitis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Cluster Headache.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT Analysis of Cluster Headache, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of acute pancreatitis, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Cluster Headache market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Cluster Headache market.

Report Insights

• Cluster Headache Patient Population Forecast
• Cluster Headache Therapeutics Market Size
• Cluster Headache Pipeline Analysis
• Cluster Headache Market Size and Trends
• Cluster Headache Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Cluster Headache Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Cluster Headache Treatment Addressable Market (TAM)
• Cluster Headache Competitive Landscape
• Cluster Headache Major Companies Insights
• Cluster Headache Price Trends and Analogue Assessment
• Cluster Headache Therapies Drug Adoption/Uptake
• Cluster Headache Therapies Peak Patient Share Analysis

Report Assessment

• Cluster Headache Current Treatment Practices
• Cluster Headache Unmet Needs
• Cluster Headache Clinical Development Analysis
• Cluster Headache Emerging Drugs Product Profiles
• Cluster Headache Market Attractiveness
• Cluster Headache Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the acute pancreatitis market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Cluster Headache?
• What are the disease risks, burdens, and unmet needs of Cluster Headache? What will be the growth opportunities across the 7MM concerning the patient population with Cluster Headache?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Cluster Headache? What are the current guidelines for treating acute pancreatitis in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Cluster Headache market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Cluster Headache

4. Key Events of Cluster Headache

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of . Cluster Headache

6. Cluster Headache Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Cluster Headache By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Cluster Headache By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Cluster Headache

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Stages and Clinical presentation of Cluster Headache
• 7.4. Causes
• 7.5. Pathogenesis
• 7.6. Diagnosis
  • 7.6.1. Diagnostic Algorithm
  • 7.6.2. Diagnostic Approach
  • 7.6.3. Diagnostic Recommendations
• 7.7. Differential Diagnosis

8. Treatment and Guidelines of Cluster Headache

• 8.1. General Management
• 8.2. Treatment Algorithm
• 8.3. Treatment Recommendations

9. Epidemiology and Patient Population of Cluster Headache

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Total Incident Cases of Cluster Headache in the 7MM
  • 9.2.2. Treated Cases of Cluster Headache in the 7MM
• 9.3. The US
  • 9.3.1. Total Prevalent Cases of Cluster headache in the US
  • 9.3.2. Diagnosed Prevalent Cases of Cluster headache in the US
  • 9.3.3. Type-specific Diagnosed Prevalent Cases of Cluster headache in the US
  • 9.3.4. Gender-specific Diagnosed Prevalent Cases of Cluster headache in the US
  • 9.3.5. Age-specific Diagnosed Prevalent Cases of Cluster headache in the US
  • 9.3.6. Treated Cases of Cluster Headache in the US
• 9.4. EU4 and the UK
  • 9.4.1. Total Prevalent Cases of Cluster headache in EU4 and the UK
  • 9.4.2. Diagnosed Prevalent Cases of Cluster headache in EU4 and the UK
  • 9.4.3. Type-specific Diagnosed Prevalent Cases of Cluster headache in EU4 and the UK
  • 9.4.4. Gender-specific Diagnosed Prevalent Cases of Cluster headache in EU4 and the UK
  • 9.4.5. Age-specific Diagnosed Prevalent Cases of Cluster headache in EU4 and the UK
  • 9.4.6. Treated Cases of Cluster Headache in EU4 and the UK
• 9.5. Japan
  • 9.5.1. Total Prevalent Cases of Cluster headache in Japan
  • 9.5.2. Diagnosed Prevalent Cases of Cluster headache in Japan
  • 9.5.3. Type-specific Diagnosed Prevalent Cases of Cluster headache in Japan
  • 9.5.4. Gender-specific Diagnosed Prevalent Cases of Cluster headache in Japan
  • 9.5.5. Age-specific Diagnosed Prevalent Cases of Cluster headache in Japan
  • 9.5.6. Treated Cases of Cluster Headache in Japan

10. Patient Journey of Cluster Headache

11. Marketed Therapies of Cluster Headache

• 11.1. Competitive Landscape of Marketed Therapies
• 11.2. Galcanezumab (EMGALITY): Eli lilly
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Safety and Efficacy
  • 11.2.6. Analyst's View

12. Cluster Headache: 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Cluster Headache in the 7MM
• 12.6. The United States Market Size
  • 12.6.1. Total Market Size of Cluster Headache in the United States
  • 12.6.2. Market Size of Cluster Headache by Therapies in the United States
• 12.7. EU4 and the UK Market Size
  • 12.7.1. Total Market Size of Cluster Headache in EU4 and the UK
  • 12.7.2. Market Size of Cluster Headache by Therapies in EU4 and the UK
• 12.8. Japan Market Size
  • 12.8.1. Total Market Size of Cluster Headache in Japan
  • 12.8.2. Market Size of Cluster Headache by Therapies in Japan

13. Unmet Needs of Cluster Headache

14. SWOT Analysis of Cluster Headache

15. KOL Views of Cluster Headache

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Cluster Headache

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Cluster Headache Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight